Previous studies have shown that deletions and inactivating mutations in the tumor suppressor ATM (Schaffner et al., 2000) or TP53 (Greiner et al., 1996) may play a role in MCL development (Figure 1C). This evidence concerns the gene TP53 and mantle cell lymphoma.